MX2021012335A - Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. - Google Patents
Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.Info
- Publication number
- MX2021012335A MX2021012335A MX2021012335A MX2021012335A MX2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A MX 2021012335 A MX2021012335 A MX 2021012335A
- Authority
- MX
- Mexico
- Prior art keywords
- ret
- antibodies
- conditions
- signaling
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832218P | 2019-04-10 | 2019-04-10 | |
| PCT/US2020/027554 WO2020210551A1 (en) | 2019-04-10 | 2020-04-09 | Human antibodies that bind ret and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012335A true MX2021012335A (es) | 2021-11-12 |
Family
ID=70554175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012335A MX2021012335A (es) | 2019-04-10 | 2020-04-09 | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220185900A1 (https=) |
| EP (1) | EP3953390A1 (https=) |
| JP (3) | JP7511576B2 (https=) |
| KR (1) | KR20210150509A (https=) |
| CN (1) | CN113993898B (https=) |
| AU (1) | AU2020270966B2 (https=) |
| CA (1) | CA3134258A1 (https=) |
| IL (1) | IL287067A (https=) |
| MA (1) | MA55615A (https=) |
| MX (1) | MX2021012335A (https=) |
| WO (1) | WO2020210551A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024503508A (ja) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
| BR112023015561A2 (pt) | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| US20250154236A1 (en) * | 2022-01-31 | 2025-05-15 | Glaxosmithkline Intellectual Property (No. 3) Limited | Prevention and treatment of headaches |
| EP4518905A1 (en) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| JP2025525904A (ja) | 2022-08-03 | 2025-08-07 | シージェン インコーポレイテッド | 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| TW202541841A (zh) * | 2023-12-20 | 2025-11-01 | 美商黛安瑟斯醫療運營公司 | 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US20090202562A1 (en) * | 2005-06-17 | 2009-08-13 | Biogen Idec Ma Inc. | Anti-gfralpha3 antibodies |
| EP1941909A4 (en) * | 2005-10-24 | 2012-05-23 | Takeda Pharmaceutical | PREVENTIVE MEASURES / REMEDIES FOR CANCER |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| PT2387583T (pt) | 2009-01-14 | 2018-12-24 | Ablynx Nv | Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos |
| PT2438087T (pt) | 2009-06-05 | 2017-08-04 | Ablynx Nv | Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| GB201512215D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| KR101859576B1 (ko) * | 2016-06-30 | 2018-05-18 | 가톨릭대학교 산학협력단 | Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도 |
| AU2018336785B2 (en) * | 2017-09-20 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
-
2020
- 2020-04-09 MX MX2021012335A patent/MX2021012335A/es unknown
- 2020-04-09 KR KR1020217036432A patent/KR20210150509A/ko active Pending
- 2020-04-09 AU AU2020270966A patent/AU2020270966B2/en active Active
- 2020-04-09 WO PCT/US2020/027554 patent/WO2020210551A1/en not_active Ceased
- 2020-04-09 CA CA3134258A patent/CA3134258A1/en active Pending
- 2020-04-09 US US17/602,562 patent/US20220185900A1/en active Pending
- 2020-04-09 CN CN202080042521.7A patent/CN113993898B/zh active Active
- 2020-04-09 EP EP20724257.9A patent/EP3953390A1/en active Pending
- 2020-04-09 MA MA055615A patent/MA55615A/fr unknown
- 2020-04-09 JP JP2021559435A patent/JP7511576B2/ja active Active
-
2021
- 2021-10-07 IL IL287067A patent/IL287067A/en unknown
-
2024
- 2024-01-11 JP JP2024002528A patent/JP7688175B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085725A patent/JP2025113406A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL287067A (en) | 2021-12-01 |
| AU2020270966B2 (en) | 2025-05-15 |
| JP7511576B2 (ja) | 2024-07-05 |
| CA3134258A1 (en) | 2020-10-15 |
| JP7688175B2 (ja) | 2025-06-03 |
| US20220185900A1 (en) | 2022-06-16 |
| JP2024024114A (ja) | 2024-02-21 |
| AU2020270966A1 (en) | 2021-10-28 |
| KR20210150509A (ko) | 2021-12-10 |
| EP3953390A1 (en) | 2022-02-16 |
| WO2020210551A1 (en) | 2020-10-15 |
| CN113993898B (zh) | 2025-05-27 |
| JP2022527373A (ja) | 2022-06-01 |
| JP2025113406A (ja) | 2025-08-01 |
| MA55615A (fr) | 2022-02-16 |
| CN113993898A (zh) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| ZA202203511B (en) | Disrupting tumor tissues by targeting fibroblast activation protein (fap) | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| AR120223A1 (es) | Proteínas que unen nkg2d, cd16 y flt3 | |
| WO2019094692A3 (en) | Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment | |
| PH12021552829A1 (en) | T cell manufacturing compositions and methods | |
| ES2422605T3 (es) | Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| MY169165A (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| PE20180131A1 (es) | Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer | |
| MX420412B (es) | Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. | |
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX343227B (es) | Anticuerpos anti-erbb3. | |
| CR20120490A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| SA520420109B1 (ar) | أجسام مضادة | |
| NI201500002A (es) | Agentes de unión de rspo3 y usos de los mismos. | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
| MX2016008072A (es) | Compuestos al receptor-3 del factor de crecimiento del fibroplasto (fgfr3) y metodos de tratamiento. | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| BR112014016652A2 (pt) | construtos de mhc parciais e médodos de uso |